Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share this content! On (X network) By

Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies Publisher Pubmed

Salarinia R^{1, 2} ; Sahebkar A³ ; Peyvandi M^{4, 5} ; Mirzaei HR⁶ ; Jaafari MR⁷ ; Riahi MM¹ ; Ebrahimnejad H⁸ ; Nahand JS¹ ; Hadjati J⁹ ; Asrami MO¹⁰ ; Fadaei S¹¹ ; Salehi R¹² ; Mirzaei H¹

Show Affiliations

1. Department of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2. Department of Medical Biotechnology, School of Medicine, North khorasan University of Medical Sciences, Bojnourd, Iran
3. Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
4. Department of Anatomical Sciences, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
5. Department of Anatomical Sciences, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran
6. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
7. Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
8. Department of Oral and Maxillofacial Radiology, Maxillofacial Diseases Research Center, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran
9. Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
10. Department of Cellular and Molecular Biotechnology, Islamic Azad University of Tonekabon, Mazandaran, Iran
11. Student Research Committee, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran
12. Department of Medical Genetics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Current Cancer Drug Targets Published:2016

Abstract

Epigenetic modifications determine phenotypic characteristics in a reversible, stable and genotype-independent manner. Epigenetic modifications mainly encompass CpG island methylation and histone modifications, both being important in the pathogenesis of malignancies. The reversibility of epigenetic phenomenon provides a suitable therapeutic option that is reactivation of epigenetically silenced tumor-suppressor genes. Inhibition of DNA methyltransferase, histone deacetylase and Aurora B kinase, individually or collectively, could feasibly prevent or reverse the impact of epigenetic silencing. MicroRNAs [miRNAs] are an important layer of epigenetic controlling of gene expression, and serve as diagnostic and prognostic biomarkers as well as treatment targets for several types of cancer. miRNAs are involved inepigenetically silencing or activation of genes, tumor suppressor genes and oncogenes, and their modulation opens new horizons for designing novel cancer therapeutic agents. © 2016 Bentham Science Publishers.

Related Docs

View other Related Docs

1. Sirna and Epigenetic Aberrations in Ovarian Cancer, Journal of Cancer Research and Therapeutics (2016)

2. Regulation of Dna Methylation Machinery by Epi-Mirnas in Human Cancer: Emerging New Targets in Cancer Therapy, Cancer Gene Therapy (2021)

3. Epi-Mirnas: Regulators of the Histone Modification Machinery in Human Cancer, Journal of Oncology (2022)

4. The Role of Dietary Polyphenols in Alternating Dna Methylation in Cancer, Critical Reviews in Food Science and Nutrition (2023)

5. Microrna in Leukemia: Tumor Suppressors and Oncogenes With Prognostic Potential, Journal of Cellular Physiology (2019)

6. Micrornas: Key Players in Virus-Associated Hepatocellular Carcinoma, Journal of Cellular Physiology (2019)

7. Involvement of Aberrant Regulation of Epigenetic Mechanisms in the Pathogenesis of Parkinson's Disease and Epigenetic-Based Therapies, Journal of Cellular Physiology (2019)

8. Emerging Biologic and Clinical Implications of Mir-182-5P in Gynecologic Cancers, Clinical and Translational Oncology (2024)

Experts (# of related papers)

View all Related Experts

Mohammadreza Sharifi (16)

Rasoul Salehi (7)

Other Related Docs

9. Melatonin Affects the Expression of Microrna-21: A Mini-Review of Current Evidence, Pathology Research and Practice (2024)

10. Inducing Cell Proliferative Prevention in Human Acute Promyelocytic Leukemia by Mir-182 Inhibition Through Modulation of Casp9 Expression, Biomedicine and Pharmacotherapy (2017)

11. A Review on Expression and Regulatory Mechanisms of Mir-337-3P in Cancer, Journal of Biomolecular Structure and Dynamics (2024)

12. Belinostat Effects on Expression of Rbm5 Tumor Suppressor Gene and Inhibits Prostate Cancer Cell Line (Pc3) Proliferation, Electronic Journal of General Medicine (2018)

13. Effects of Caloric Restriction on Delaying the Aging Process, Journal of Isfahan Medical School (2013)

14. Circular Rnas: New Genetic Tools in Melanoma, Biomarkers in Medicine (2020)

15. Microrna Dysregulation and Its Impact on Apoptosis-Related Signaling Pathways in Myelodysplastic Syndrome, Pathology Research and Practice (2024)

16. The Role of Microrna-30A and Downstream Snail1 on the Growth and Metastasis of Melanoma Tumor, Iranian Journal of Basic Medical Sciences (2019)

17. Circulating Micrornas As Potential Diagnostic Biomarkers and Therapeutic Targets in Gastric Cancer: Current Status and Future Perspectives, Current Medicinal Chemistry (2016)

18. Ezh2-Interacting Lncrnas Contribute to Gastric Tumorigenesis; a Review on the Mechanisms of Action, Molecular Biology Reports (2024)

19. Bioinformatics Prediction and Experimental Validation of a Novel Microrna: Hsa-Mir-B43 Within Human Cdh4 Gene With a Potential Metastasis-Related Function in Breast Cancer, Journal of Cellular Biochemistry (2020)

20. The Prominent Role of Mir-942 in Carcinogenesis of Tumors, Advanced Biomedical Research (2022)

21. Inhibition of Microrna Mir-222 With Lna Inhibitor Can Reduce Cell Proliferation in B Chronic Lymphoblastic Leukemia, Indian Journal of Hematology and Blood Transfusion (2017)

22. Apoptosis-Inducing and Antiproliferative Effect by Inhibition of Mir-182-5P Through the Regulation of Casp9 Expression in Human Breast Cancer, Cancer Gene Therapy (2017)

23. Study of the Role of Sirna Mediated Promoter Methylation in Dnmt3b Knockdown and Alteration of Promoter Methylation of Cdh1, Gstp1 Genes in Mda-Mb -453 Cell Line, Iranian Journal of Pharmaceutical Research (2017)

24. Locked Nucleic Acid Anti-Mir-21 Inhibits Cell Growth and Invasive Behaviors of a Colorectal Adenocarcinoma Cell Line: Lna-Anti-Mir As a Novel Approach, Cancer Gene Therapy (2016)

25. Exploring Conserved Mrna-Mirna Interactions in Colon and Lung Cancers, Gastroenterology and Hepatology from Bed to Bench (2017)

26. Degradation of Mir-21 Induces Apoptosis and Inhibits Cell Proliferation in Human Hepatocellular Carcinoma, Cancer Gene Therapy (2015)

27. The Effect of Decitabine on the Expression and Methylation of the Ppp1ca, Btg2, and Pten in Association With Changes in Mir-125B, Mir-17, and Mir-181B in Nalm6 Cell Line, Journal of Cellular Biochemistry (2019)

28. Recent Insights Into the Microrna-Dependent Modulation of Gliomas From Pathogenesis to Diagnosis and Treatment, Cellular and Molecular Biology Letters (2022)

29. Mir-196: Emerging of a New Potential Therapeutic Target and Biomarker in Colorectal Cancer, Molecular Biology Reports (2020)

30. Modulation of Long Non-Coding Rnas and Micrornas by Quercetin As a Potential Therapeutical Approach in Cancer: A Comprehensive Review, Current medicinal chemistry (2025)

31. Current Status and Perspectives Regarding Lna-Anti-Mir Oligonucleotides and Microrna Mir-21 Inhibitors As a Potential Therapeutic Option in Treatment of Colorectal Cancer, Journal of Cellular Biochemistry (2017)

32. Dna Methylation and Microrna Patterns Are in Association With the Expression of Brca1 in Ovarian Cancer, Cellular and Molecular Biology (2016)

33. Inhibition of Microrna Mir-92A Inhibits Cell Proliferation in Human Acute Promyelocytic Leukemia; [Mikrorna Mir-92A Inhibisyonu Insan Akut Promyelositik Losemide Hucre Proliferasyonunu Inhibe Eder], Turkish Journal of Hematology (2013)

34. Functional Roles of Lncrnas in Recurrent Pregnancy Loss: A Review Study, International Journal of Fertility and Sterility (2023)

35. The Significant Role of Micrornas in Gliomas Angiogenesis: A Particular Focus on Molecular Mechanisms and Opportunities for Clinical Application, Cellular and Molecular Neurobiology (2023)

36. Deciphering the Multifaceted Role of Micrornas in Hepatocellular Carcinoma: Integrating Literature Review and Bioinformatics Analysis for Therapeutic Insights, Heliyon (2024)

37. Evaluation of the Effect of Tim-3 Suppression by Mir-498 and Its Effect on Apoptosis and Proliferation Rate of Hl-60 Cell Line, Pathology Research and Practice (2018)

38. Therapeutic Inhibition of Microrna-21 (Mir-21) Using Locked-Nucleic Acid (Lna)-Anti-Mir and Its Effects on the Biological Behaviors of Melanoma Cancer Cells in Preclinical Studies, Cancer Cell International (2020)

39. The Role of Mir-16 and Mir-34A Family in the Regulation of Cancers: A Review, Heliyon (2025)

40. Mir-574, Mir-499, Mir-125B, Mir-106A, and Mir-9 Potentially Target Tgfbr-1 and Tgfbr-2 Genes Involving in Inflammatory Response Pathway: Potential Novel Biomarkers for Chronic Lymphocytic Leukemia, Pathology Research and Practice (2022)

41. Emerging Roles of Jmjd3 in Cancer, Clinical and Translational Oncology (2022)

42. Micrornas Regulating Wnt Signaling Pathway in Colorectal Cancer: Biological Implications and Clinical Potentials, Functional and Integrative Genomics (2022)

43. Micrornas in Female Infertility: An Overview, Cell Biochemistry and Function (2021)

44. The Mir-125A-3P Inhibits Tim-3 Expression in Aml Cell Line Hl-60 in Vitro, Indian Journal of Hematology and Blood Transfusion (2017)

45. Apoptosis Induction in Acute Promyelocytic Leukemia Cells Through Upregulation of Cebpα by Mir-182 Blockage, Molecular Biology Research Communications (2018)

46. Lna Inhibitor in Microrna Mir-23B As a Potential Anti-Proliferative Option in Human Hepatocellular Carcinoma, Journal of Gastrointestinal Cancer (2020)

47. The Role of Lncrna Mcm3ap-As1 in Human Cancer, Clinical and Translational Oncology (2023)

48. Mir-939, As an Important Regulator in Various Cancers Pathogenesis, Has Diagnostic, Prognostic, and Therapeutic Values: A Review, Journal of the Egyptian National Cancer Institute (2024)

49. Micrornas and Target Molecules in Bladder Cancer, Medical Oncology (2020)

50. Non-Coding Rnas and Glioblastoma: Insight Into Their Roles in Metastasis, Molecular Therapy Oncolytics (2022)

Style	Citing Format
MLA	Salarinia R, et al.. "Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies." Current Cancer Drug Targets, vol. 16, no. 9, 2016, pp. 773-788.
APA	Salarinia R, Sahebkar A, Peyvandi M, Mirzaei HR, Jaafari MR, Riahi MM, Ebrahimnejad H, Nahand JS, Hadjati J, Asrami MO, Fadaei S, Salehi R, Mirzaei H (2016). Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies. Current Cancer Drug Targets, 16(9), 773-788.
Chicago	Salarinia R, Sahebkar A, Peyvandi M, Mirzaei HR, Jaafari MR, Riahi MM, Ebrahimnejad H, et al.. "Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies." Current Cancer Drug Targets 16, no. 9 (2016): 773-788.
Harvard	Salarinia R et al. (2016) 'Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies', Current Cancer Drug Targets, 16(9), pp. 773-788.
Vancouver	Salarinia R, Sahebkar A, Peyvandi M, Mirzaei HR, Jaafari MR, Riahi MM, et al.. Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies. Current Cancer Drug Targets. 2016;16(9):773-788.
BibTex	@article{ author = {Salarinia R and Sahebkar A and Peyvandi M and Mirzaei HR and Jaafari MR and Riahi MM and Ebrahimnejad H and Nahand JS and Hadjati J and Asrami MO and Fadaei S and Salehi R and Mirzaei H}, title = {Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies}, journal = {Current Cancer Drug Targets}, volume = {16}, number = {9}, pages = {773-788}, year = {2016} }
RIS	TY - JOUR AU - Salarinia R AU - Sahebkar A AU - Peyvandi M AU - Mirzaei HR AU - Jaafari MR AU - Riahi MM AU - Ebrahimnejad H AU - Nahand JS AU - Hadjati J AU - Asrami MO AU - Fadaei S AU - Salehi R AU - Mirzaei H TI - Epi-Drugs and Epi-Mirs: Moving Beyond Current Cancer Therapies JO - Current Cancer Drug Targets VL - 16 IS - 9 SP - 773 EP - 788 PY - 2016 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract